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CDC in Kenya
Our Mission: To protect and improve health in Kenya and globally 
through science, communication, policy, partnership, and evidence-
based public health action. 
For 40 years, the Centers for Disease 
Control and Prevention (CDC) has 
helped strengthen public health 
and laboratory systems in Kenya, 
creating an integrated research 
and program center. This model 
ties together multiple program 
areas, leveraging technical skills 
and a strong partnership with 
the Government of Kenya to 
build sustainable public health 
capacity. CDC Kenya saves lives 
by conducting research on the 
effectiveness of new interventions 
and by preventing disease, 
reducing death and disability, and 
implementing evidence-based 
public health programs. 
Four Decades Forward:  
CDC Kenya Celebrates 40th Anniversary
Colleagues and Friends,
It was in 1979, 40 years ago, that CDC initiated work in Kenya. As always, chance played an 
important role in choices made and developments that ensued. The big CDC was established in 
1946 as an infectious disease control agency succeeding the Malaria Control in War Areas unit 
that was set up in Atlanta early during World War II. Tropical medicine and infectious challenges 
in faraway places have been integral to CDC’s character from its earliest days. In the mid-1960s 
CDC took on a leadership role in malaria eradication efforts, with the late Robert Kaiser, a former EIS officer, heading the effort. 
Kaiser later became head of CDC’s parasitic diseases program and in 1979 assigned one of his staff, Harrison Spencer, to initiate 
malaria research in Kenya. Chloroquine resistance had just been described in East Africa and a technique to culture Plasmodium 
falciparum outside of the human body had been recently introduced. “Why Kenya?” one may ask. Certainly, there was enough 
malaria to study, and the country’s research and educational infrastructure was strong. Undoubtedly, however, other issues were 
relevant; Kaiser had met his wife in Nairobi, and felt a lifelong affinity with the country.
A small but vibrant Kenyan and international tropical medicine community existed in Nairobi in 1979, working on malaria, 
leishmaniasis, schistosomiasis, filariasis, hydatid disease and other conditions. Harrison divided his time between Nairobi and 
western Kenya where he conducted his fieldwork. The Kenya Medical Research Institute (KEMRI) was established at the same 
time, explaining the strong links between the Kenya Ministry of Health, KEMRI and CDC that have endured over time. The malaria 
work increased in complexity and scope, giving insight not only into basic science but also burden of disease and epidemiology. 
Interventional work was emphasized such as the large evaluation of insecticide-impregnated bed nets, prevention and 
management of malaria in pregnancy, and vaccine trials. CDC staff came and went, but over time, a full-time CDC presence was 
established in Kisumu, working out of the KEMRI campus in Kisian.
By the time the first case of AIDS was described in Kenya in 1984, silent spread of HIV was already extensive and the region 
around Lake Victoria was the most heavily affected. CDC decided in the early 2000s to expand its research to include HIV, 
and the advent of the Global Fund to Fight AIDS, Tuberculosis and Malaria and the President’s Emergency Plan for AIDS Relief 
(PEPFAR) shortly thereafter fundamentally changed the landscape. Increased funding for other areas such as emerging infectious 
diseases and a broader vision of the requirements of global health—recognition that U.S. domestic health was related to health 
everywhere—led to substantial CDC expansion. Evolution led to CDC Kenya becoming the agency’s most diverse overseas office, 
working programmatically as well as on research for HIV/AIDS, malaria, tuberculosis, influenza and other infectious diseases and 
public health issues, and conducting regulatory functions for immigrants and refugees traveling to the United States.
One of CDC’s contributions apart from conducting research and program work has been to support the development of scientific 
and public health leadership in Kenya. Through the Kenya Field Epidemiology and Laboratory Training Program (FELTP) and the 
related Improving Public Health Management for Action (IMPACT) program, CDC has offered hands-on, in-the-field training to 
the next generation of epidemiologists and public health leaders. These programs have produced over 300 graduates, many of 
whom have gone on to hold leadership positions in the Ministry of Health and other organizations in Kenya and internationally.
I am pleased to share this report with you, one that tells the story of CDC in Kenya over the last year. We sincerely thank all 
partners and the Government of Kenya for their work that does so much to make Kenya a safer and healthier country. CDC Kenya 
would not be where it is today without the contributions and commitment of all our staff over the past 40 years, emphasizing 
that the greatest asset of any successful organization is its people. I salute them all. We dedicate this report to the memory of Dr. 
Harrison Spencer who started it all.
Sincerely,
Kevin M. De Cock, MD, FRCP (UK), DTM&H
CDC Kenya Country Director
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CDC’s IMPACT in 2018
630,000  
PEOPLE 
630,000 people are 
on life-saving  
antiretroviral  
therapy.
400,000  
WOMEN
More than 400,000 
pregnant women  
know their HIV  
status. Of those tested 
positive, 99% are on 
treatment.
92%  
OF PEOPLE 
LIVING  
WITH HIV 
92% of patients living 
with HIV and on CDC-
supported treatment 
have suppressed HIV 
to undetectable levels in 
their blood.
25  
OUTBREAKS
25 outbreak  
investigations  
supported 
107  
ARTICLES
107 peer-reviewed  
scientific articles  
published  
or in press
Timeline of Key Events in 
CDC Kenya History
1979
Dr. Harrison Spencer 
establishes field 
research center for 
malaria in Kenya as 
antimalarial resistance 
emerged in Africa
1979
Launch of partnership 
between CDC and 
KEMRI
1979
Evaluation of 
schistosomiasis 
morbidity in relation  
to the intensity  
of exposure
1979–1982
Saradidi Rural Health 
Project was the first 
major population study 
in East Africa 
1980s
Malaria research 
continues in drug 
resistance, immune 
response, and 
entomological 
interventions
1992–
1999
Asembo Bay Cohort 
Project—Longitudinal 
study on childhood 
illnesses in 15 villages
1994
Identification of unsafe 
blood supply 
1996–2001
Malaria Insectide-
treated Bednet Trial 
1997
HIV, Schistosomiasis, 
and reinfection
1997
Global Enterics 
Multicenter Study 
(GEMS)
1999
AIDS declared a 
national disaster by 
President Moi
2000
Leadership and 
Investment in Fighting 
Epidemics (LIFE) 
Initiative
2001
Voluntary counseling 
and testing (VCT) 
guidelines
2002
Launch of the Health 
and Demographic 
Surveillance System 
(HDSS) in Siaya
2003
Kisumu Breastfeeding 
Study saw reduction 
mother to child 
transmission of HIV
2004
Launch of the 
President’s Emergency 
Plan for AIDS Relief
2004
Launch of the Global 
Disease Detection Center
2004
Launch of the Kenya 
Field Epidemiology and 
Laboratory Training 
Program (FELTP)
2004
TB prevalence study 
and TB lab established
2005
Launch of the  
Influenza Program
2007
Launch of the  
Global Migration  
and Quarantine  
Africa Program
2008
Kenya joins the 
President’s Malaria 
Initiative (PMI)
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2009
Phase III Clinical Trial for 
RTS,S malaria vaccine
2009
HIV Research 
Laboratory the first 
to be ISO accredited 
outside of Atlanta
2009
PEPFAR I ends and 
PEPFAR II starts
2011
Establishment of  
the Kenya Zoonotic 
Disease Unit
2012
Kenya AIDS Indicator 
Survey (KAIS)
2014–2015
CDC Kenya staff 
respond to the Ebola 
epidemic in West Africa
2014
Launch Global Health 
Security Agenda
2014
Second KAIS
2015
Release of the Strategic 
Timing of AntiRetroviral 
Treatment (START) results
2015
Launch of the 
Determined, Resilient, 
Empowered, AIDS-free, 
Mentored, and Safe 
(DREAMS) program
2016
Launch of the 
Improving Public 
Health Management 
for Action (IMPACT) 
program
2016
Selected as Bill 
and Melinda Gates 
Foundation Child 
Health and Mortality 
Prevention Surveillance 
(CHAMPS) site
2016
Initiation of “Test and 
Treat” and pre-exposure 
prophylaxis strategies 
for HIV
2016
Clinical Research 
Center in western 
Kenya selected as 
HIV Prevention Trials 
Network (HPTN) site
2017
Kenya Public Health 
Emergency Operations 
Center activates for 
national cholera outbreak
2017
Launched CHAMPS 
site in western 
Kenya offering new 
insights into under 5 
childhood deaths.
2018
Kenya completes Joint 
External Evaluation 
(JEE) for Health Security
2018
Kenya Population-
Based HIV Impact 
Assessment Survey 
(KENPHIA)
2018
Kenya selected for 
expanded pilot of RTS,S 
malaria vaccine
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Acronyms
ACRONYM DEFINITION
AMP Antibody-mediated Prevention
ANC Antenatal Care 
ART Antiretroviral Treatment
BMT Budget Marked-up Tool
CDC Centers for Disease Control and Prevention
cMIS Continuous Malaria Indicator Survey 
CoAg Cooperative Agreement
CS Cabinet Secretary
CHAMPS Child Health and Mortality Prevention Surveillance
DOD Department of Defense
DP Dihydroartemisinin-piperaquine
EID Early Infant Diagnosis
EGPAF Elizabeth Glaser Pediatric AIDS Foundation 
FELTP Field Epidemiology and Laboratory  
Training Program
GBV Gender-based Violence 
GOK Government of Kenya
HPTN HIV Prevention Trials Network
IMPACT Improving Management for Public Health Action
KEMRI Kenya Medical Research Institute
KENITAG Kenya National Immunization Technical  
Advisory Group
ACRONYM DEFINITION
LIFE Long-acting Injectable for the Epidemic
LSTM Liverpool School of Tropical Medicine 
mHealth Mobile Health
MOH Ministry of Health
NASCOP National AIDS and STI Control Program
NGS Next Generation Sequencing
NIH National Institutes of Health
OCV Oral Cholera Vaccine 
OTZ Operation Triple Zero
PCR Polymerase Chain Reaction 
PEPFAR President’s Emergency Plan for AIDS Relief
POE Ports of Entry
RVF Rift Valley fever 
SMS Short Message System
TB Tuberculosis
UCSF University of California, San Francisco 
USAID U.S. Agency for International Development 
VL Viral Load
WASH Water, Sanitation and Hygiene
WHO World Health Organization
Xpert Ultra Xpert MTB/RIF Ultra
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Science
CDC Kenya conducts and translates research to inform policy and 
practice both in Kenya and globally; and to monitor and evaluate 
activities that ensure cost-effective health impact.
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New Tools to Fight Malaria in Western Kenya
In Kenya, malaria remains a leading cause of illness 
and death. Since 1979, CDC has collaborated on 
malaria research projects in western Kenya, which 
harbors the largest burden of disease in the country. 
In 2018, CDC Kenya’s malaria research program 
made headway in evaluating new prevention and 
treatment tools in the fight against malaria.
New study shows drug that kills 
mosquitoes could be used to fight malaria
One of these studies has shown the potential 
impact of a new drug strategy for breaking the 
transmission cycle of malaria. The study showed 
that when a mosquito bites a person who has 
taken ivermectin, an anti-parasitic drug, within the 
last 28 days, that the mosquito dies, thus breaking 
the malaria transmission cycle. This differs from 
existing drugs that target the parasite to reduce 
the spread of malaria.
For this study a team of scientists from CDC 
Kenya, KEMRI, the Liverpool School of Tropical 
Medicine (LSTM), and other organizations, carried 
out a randomized controlled trial. The results 
were published in June 2018 in Lancet Infectious 
Diseases, and show that adding high doses of 
ivermectin to the antimalarial dihydroartemisinin-
piperaquine (DP) has a major and prolonged effect 
on mosquito mortality.
“This first evaluation of the impact of high dose 
ivermectin on mosquito mortality is highly 
encouraging and requires further evaluation in 
larger scale trials that target both malaria parasites 
and the mosquitos, as the world pushes towards 
malaria elimination”, explained LSTM’s Professor 
Feiko ter Kuile, senior author of the paper.
Ramping up disease surveillance
Disease surveillance systems are the backbone 
of all public health systems providing the data 
necessary to monitor trends, show the impact 
of interventions, estimate testing and treatment 
commodity needs, and identify and respond to 
outbreaks. Malaria surveillance poses a specific 
challenge; the majority of cases of malaria 
in western Kenya do not result in disease, 
and therefore case counts at health facilities 
substantially underestimate the burden in the 
community. Cross-sectional studies, which have 
traditionally been the gold-standard, are not 
sustainable due to their expense.
Understanding this, CDC invested resources over 
the last 3 years to investigate both new systems 
and novel ways for using existing systems to 
monitor malaria in the community. The first step 
was creating a continuous malaria indicator survey 
(cMIS) that is used for collecting data every working 
day of the year. This system provides the gold-
standard for testing whether other approaches 
can accurately detect real-time trends in malaria 
infection. Next, the team focused on evaluating 
more sustainable methods for performing malaria 
surveillance. One such method determines 
whether positive malaria tests in pregnant women 
attending their first antenatal care (ANC) clinic visit 
accurately estimate malaria infection prevalence in 
the community. After 2.5 years of data collection, 
analyses demonstrates that women attending 
first ANC clinic visits show a strong correlation 
with community infection prevalence and may 
supplement existing surveillance systems. Initial 
study results were presented at the 2018 American 
Society of Tropical Medicine and Hygiene Annual 
Conference in New Orleans. Based upon this 
cutting-edge work in Kenya, the President’s Malaria 
Initiative is performing pilot evaluations in four 
other sub-Saharan African countries. 
The CDC team’s next challenge is to evaluate use of 
this system to identify hotspots of malaria disease, 
and direct the appropriate response for targeted 
interventions. This important work has begun in 
earnest and will be the focus of the CDC Kenya’s 
malaria surveillance studies for 2019 and 2020.
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“The FELTP program imparted me with key practical skills  
in public health surveillance and data analysis that I use  
in my work everyday.” Dr. Ngina Kisengau
Informing Global Policy on the Use of 
Molecular TB Diagnostics
Tuberculosis (TB) is the leading infectious disease 
killer in the world. According to the World Health 
Organization (WHO), 1.6 million people died from 
the disease in 2017, including 230,000 children1. 
One key to controlling TB is effective testing of 
those showing the signs and symptoms. While 
sputum smear microscopy remains the foundation 
of TB diagnosis in low- and middle-income 
countries, the test sensitivity is poor, especially 
in people living with HIV. Mycobacterial culture 
is considered the gold standard for definitive 
diagnosis of TB but it proves challenging in poorly 
resourced settings. Clinicians and public health 
officials urgently need new and improved tools for 
diagnosing TB. 
CDC Kenya, in collaboration with the Kenya 
Medical Research Institute (KEMRI) and the Clinical 
Diagnostics Research Consortium, participated in a 
landmark multi-country evaluation of the molecular 
TB diagnostic assay, Xpert MTB/RIF Ultra (Xpert 
Ultra). Funded by the U.S. National Institutes of 
Health (NIH), this was the first prospective study on 
the accuracy of Xpert Ultra for pulmonary (involving 
the lungs) TB and the detection of drug resistance. 
The study showed that Xpert Ultra was a superior 
test in diagnosing TB. Additionally, Xpert Ultra did 
not require any equipment changes to the existing 
GeneXpert technology beyond a new cartridge. 
The findings of this study, published in Lancet 
Infectious Diseases2, were used by the WHO to 
endorse Xpert Ultra for TB diagnosis for all adults 
and children with signs of TB. 
1 WHO—https://www.who.int/news-room/fact-sheets/detail/tuberculosis
2 Findings from this landmark study were used by WHO to endorse Xpert Ultra for TB diagnosis for all adults and children with signs and 
symptoms of TB. 
FELTP Resident Investigates  
Hepatitis B Prevalence Among Kenyan 
Healthcare Workers
The Kenya Field Epidemiology and Laboratory 
Training Program (FELTP) is a 2-year training 
program that aims to improve national and county-
level public health systems by building advanced 
skills in applied epidemiology and laboratory 
management among a variety of healthcare 
professionals. The Kenya FELTP began in 2004 and 
has since trained over 300 healthcare professionals 
who, while in the program, contribute significantly 
to investigating and responding to major outbreak 
investigations including Rift Valley fever (RVF), polio, 
and measles across the country.
Ngina Kisengau, a recent FELTP graduate and 
clinician by training, successfully responded to 
the challenge of evaluating an outbreak of viral 
hepatitis B in Makueni County. During her time as 
a FELTP resident, she was alerted of a suspected 
hepatitis B outbreak in a county prison and 
became concerned about how it might increase 
the risk of hepatitis B infection among healthcare 
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workers. Unfortunately, data on the prevalence of 
hepatitis B virus infection and vaccination rates in 
African healthcare workers are limited. Therefore, 
the Kenya FELTP (in collaboration with KEMRI, CDC 
and the Makueni County Government) proceeded 
to investigate vaccination rates and factors 
associated with hepatitis B vaccination among 
healthcare workers.
As part of the investigation, Ngina surveyed over 
300 healthcare workers in 42 health centers, 
clinics and dispensaries throughout the county 
and tested blood specimens from 95% of the 
respondents for signs of immunity against hepatitis 
B virus. The survey and blood tests helped to 
identify health workers that were less likely to be 
vaccinated against hepatitis B. Results indicated 
that although 80% of workers had received at 
least one dose of the hepatitis B vaccine, about 
half of those vaccinated did not receive all three 
recommended doses primarily because the vaccine 
was not readily available. Also, cleaners and waste 
handlers were less likely to be vaccinated compared 
to nurses, doctors, and laboratorians. These 
valuable conclusions were shared with county 
representatives and ultimately published in the 
Oxford Journal of Public Health in October 2018.
Ngina’s study also motivated Makueni County  
to acquire additional doses of hepatitis B vaccine 
for healthcare workers. Thanks to Ngina’s use  
of evidence-based data, she was ultimately able  
to protect the health of her fellow healthcare 
workers and influence vaccination efforts across 
Makueni County. 
Prevention Solutions Underway for Women 
at Western Kenya Clinical Research Site
Young women and adolescent girls remain at high 
risk for HIV, and prevention methods that are both 
acceptable and accessible to them are critical to 
their well-being. Over the past 10 years, public 
health officials and researchers have made progress 
in preventing new HIV infections through the use of 
innovative methods. Additionally, many women are 
seeking contraception to prevent pregnancy. New 
research is looking at combined methods that offer 
dual protection from both HIV and pregnancy.
The Western Kenya Clinical Research site, a 
collaboration between CDC Kenya and KEMRI, has 
been conducting high-quality clinical research 
studies for more than a decade and in recent years 
has contributed data to more than a dozen multi-
site international HIV and TB clinical trials. 
Two important studies sponsored by the National 
Institutes of Health (NIH)’s HIV Prevention Trials 
Network (HPTN) are currently underway, one of 
which has already reached its target enrollment 
of participants: the Antibody Mediated Prevention 
(AMP) study which looks at the effectiveness of a 
monoclonal antibody for the prevention of HIV; 
and the Long-acting Injectable For the Epidemic 
(LIFE) study which evaluates the safety and efficacy 
of an injectable antiretroviral, Cabotegravir, for HIV 
prevention in women. 
Further plans are underway to launch two more 
studies that will use an intravaginal ring to prevent 
HIV in women. The recent study includes a ring that 
contains both an agent to prevent HIV infection 
and a hormonal contraceptive. Additionally, the 
NIH’s Microbicide Trials Network’s REACH (Reversing 
the Epidemic in Africa with Choices in Prevention) 
study will compare adherence to an intravaginal 
ring that has an antiretroviral drug and daily 
oral pre-exposure prophylaxis targeting women 
between the ages of 16-21 years.
These studies will help protect and empower 
adolescent girls and young women in Kenya and 
around the world from getting HIV. 
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Uncovering the Genetic Fingerprint of 
Pathogens that Cause Diseases in Kenya 
Next Generation Sequencing (NGS), a technology 
that allows DNA and RNA to be sequenced much 
more quickly and cheaply, is rapidly changing the 
practice of microbiology. NGS capacity in public 
health laboratories is one of the most important 
advances in diagnosing infectious diseases over the 
last three decades because it gives each pathogen 
a unique fingerprint. 
In 2018, CDC established NGS capacity in Kenya 
to detect bacterial pathogens. The teams involved 
worked concurrently in two of CDC’s Global 
Disease Detection sites in Kenya and Thailand 
to develop this advanced capacity, provide 
training, and supply the required NGS equipment. 
Initial implementation included sequencing of 
Salmonella bacterial isolates to highlight the 
resistance patterns to commonly used antibiotics. 
The process tracks circulating bacteria in time and 
space, providing data which can be used to prevent 
spread and thus reduce disease in the Kenyan 
population.
Every year, Kenya experiences disease outbreaks 
from various pathogens. Often, health experts are 
unable to determine which disease is causing the 
outbreak. Incorporating NGS technology in the 
diagnostic capacity now allows CDC to sequence 
an entire pathogen genome to identify whether 
the pathogen is viral or bacterial, characterize 
its antimicrobial resistance, determine factors 
that increase the pathogen’s ability to cause 
severe disease as well as its typing and molecular 
epidemiology in the public health laboratory. This 
advanced technology, however, can be difficult 
to implement without the appropriate laboratory 
infrastructure and human resources.
Implementing NGS in Kenya has enabled 
laboratorians to become self-sufficient and 
problem-solve issues without external expertise. 
Once programs implement sequencing as a routine 
diagnostic technique for one enteric bacterial 
pathogen, the same methods may be applied for 
other bacterial pathogens. Scientists hope that this 
approach will set the stage for progression towards 
more complex NGS procedures including testing 
of a broader range of specimens, and increase 
capacity for detecting novel pathogens.
Kenya Paves the Way for Flu Shots  
During Pregnancy in East Africa
Expectant mothers are among those most at risk of 
developing serious complications from influenza 
(flu). When a woman becomes pregnant, changes 
to her immune system, heart, and lungs make her 
more prone to severe illness from flu, including 
illness resulting in hospitalization. 
In 2012, the World Health Organization (WHO) 
recommended that pregnant women should have 
the highest priority for seasonal flu vaccination in 
countries starting or expanding flu immunization 
programs. This is because flu vaccine has a long 
track record of safety when administered during 
pregnancy and is the best way to protect expectant 
mothers from the effects of flu. Moreover, when 
a pregnant woman is vaccinated, she produces 
protective antibodies against flu that are passed 
in-utero to her baby, protecting newborns from 
flu for the first several months of life. Infants 
younger than 6 months of age are too young to be 
vaccinated, but also are at high risk of serious flu 
complications, so the protection gained from their 
mother’s vaccination is very important. 
To guide the Kenya government as it considers 
expanding its flu vaccination program to include 
pregnant women, CDC Kenya—in collaboration 
with the Kenya Medical Research Institute 
(KEMRI)—is leading a demonstration project 
to vaccinate pregnant women in Kenya’s Siaya 
County. The study aims to enroll more than 
400 pregnant women, give them a flu vaccine 
and measure how well they develop immune 
protection after vaccination as well as measure 
the flu antibodies transferred in utero to the 
babies. The study includes vaccinating pregnant 
women who are HIV+ or who had malaria when 
vaccinated. The study began in June 2018 and has 
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already enrolled more than 100 mothers. The study 
team relate that pregnant women participating 
in the project have had positive experiences, and 
many have encouraged other pregnant women to 
participate in the study. 
Kenya has not yet adopted a flu vaccine 
recommendation for pregnant women, partly 
due to lack of local data to support such a policy. 
The current recommendation of the Kenya 
National Immunization Technical Advisory Group 
(KENITAG) focuses on children 6 to 23 months of 
age due to the high number of flu cases among 
very young children. KENITAG has also requested 
country-driven data on the impact of flu among 
pregnant women and their babies, emphasizing 
the need to understand if the flu vaccine would 
work as well in mothers who suffer from HIV 
or malaria, and if these mothers would transfer 
antibodies against flu to their babies.
CDC expects that findings from this study will inform 
decision-making by the Kenya Ministry of Health on 
the adoption of a flu vaccination policy for pregnant 
women. If adopted, this policy will serve as an 
important public health step in Kenya, and serve as 
an example to other countries in the region.
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Service
Service stands as a core tenet of CDC’s priority activities through 
the delivery and implementation of interventions for the most 
vulnerable populations. Through service delivery, CDC seeks to 
accelerate progress toward a world safe from disease threats and 
where lives are saved and health is improved.
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Members of Epedor meet and discuss life issues. The group has also helped to bolster household food security  
in the often drought-affected region of Turkana. Photos by Gibson/EGPAF
Local Men’s Club Provides Solutions to 
Improved Uptake of HIV Services in Turkana 
As Kenya continues to make gains in controlling 
the HIV epidemic, targeted strategies are 
paramount in helping to stop the spread of 
disease. In 2018, the U.S. President’s Emergency 
Plan for AIDS Relief (PEPFAR) launched the 
MenStar Coalition to accelerate the delivery of 
innovative approaches in HIV services for men. 
Recent HIV-related data show that “men are less 
likely to know their status, practice consistent 
prevention, or access treatment.”  CDC, together 
with its implementing partners, is leading the way 
to identify effective strategies that reach men so 
that they know their status, stay on treatment and 
manage their health—one such strategy is taking 
off in the remote areas of Turkana County. 
Epedor
“Epedor” loosely translated from Turkana to mean 
“it is possible” is a program that is transforming the 
lives of men in the Turkana community. Similar to 
what has been observed globally, the Lokitaung 
health facility, a CDC-supported site, has recorded 
sub-optimal viral suppression and retention among 
their male patients. Given the challenges seen in 
the health facility, program administrators with the 
Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) 
devised a differentiated service delivery model for 
men—Epedor is a tailored approach to providing 
HIV-related care for this group’s unique needs. 
Turkana is largely known to be a patriarchal society, 
where males have a strong influence over their 
families. Epedor serves as a men’s adherence club 
and a social support group that offers peer-to-peer 
learning. Through peer education sessions about 
HIV treatment, Epedor calls on participants to make 
commitments to address various aspects of their 
life, including: 
  Actions to improve their health,
  HIV testing for their spouse and children,
  Income-generating activities,
  Advocating against gender-based violence, and
  Avoiding alcohol and substance abuse. 
The men’s adherence club has led to considerable 
improvements among the males enrolled to 
date, including a reduced number of missed 
appointments, increased adherence to HIV 
treatment, and higher viral suppression rates. 
With these encouraging results, Epedor was 
quickly replicated in four other health facilities 
across Turkana. Epedor demonstrates that with a 
committed group of men, it is possible to witness 
transformative results.
3 PEPFAR Press Release, 2018. Global Partners Pledge over $1.2 Billion to Launch the MenStar Coalition
CDC KENYA 2018 ANNUAL REPORT | PAGE 18
Lucy Nkatha, the Immunization  
Champion of Meru 
A survivor of polio, Lucy Nkatha makes an 
impassioned case for immunizations when she 
meets with parents, women’s groups and others 
skeptical about vaccines. Lucy is an “immunization 
champion” and in Meru County she is at the center 
of a national Polio Immunization Campaign team. 
The team—which includes WHO, CDC, UNICEF, and 
community partners—works tirelessly to prevent 
further spread of a strain of polio circulating in 
nearby Somalia and detected in an environmental 
sample in Nairobi. 
Lucy received just one dose of the poliovirus 
vaccine as an infant in the late 1970s. As a result, 
she was not fully protected from the disease when 
at 3-years old, she became ill. Lucy was the third 
of nine children, and it was not easy for Lucy’s 
parents to access a medical facility to vaccinate 
their children from their rural village of Limauru in 
Ncooro, Meru County. 
While Lucy doesn’t remember life before polio, her 
mother Joyce does. Joyce remembers Lucy as a 
healthy, active toddler. She recalls Lucy following 
behind her older siblings when they went to the 
stream to get water and filling her own, smaller pail. 
When Lucy fell sick with polio, everything changed. 
She spent three months in the hospital, and for 
the first two months after returning home, Lucy 
couldn’t walk, move, or sit up on her own. One day, 
she began crawling, and that was how Lucy got 
around until she was 7-years old. 
Lucy’s disability made it impossible for her to walk 
the rocky hills to the primary school nearby, so she 
couldn’t attend school with her brothers and sisters. 
When a schoolteacher heard about Lucy’s situation, 
he took her to a missionary school for the disabled 
in nearby Tuuru. There, she received a cane and a 
caliper to help her walk and discovered a love for 
learning.
Twenty-five years later, Lucy is now 40-years old, 
married, and a mother to three teenage children. 
After running a hair salon for ten years, Lucy now 
focuses full-time on her family, volunteering in her 
community, and serving as a disabilities advocate 
and immunization champion. Says Lucy, “While 
I’ve managed to get beyond it, it’s very tough 
to grow up with a disability in rural Africa” and 
Lucy doesn’t want any other child to endure the 
struggles she did. This is her second time serving 
as an immunization champion for a polio vaccine 
campaign—she also supported the 2016 campaign.
During that campaign, Lucy visited the pastor of 
an indigenous faith who had warned followers 
against the polio vaccine. Sharing her story and 
the struggles she endured, she convinced the 
pastor to support the polio vaccination campaign. 
In the 2018 campaign, Lucy once again talked to 
religious leaders, parents, and women’s groups 
about the importance of vaccinating every eligible 
child, every time the vaccinators come around. And 
again, Lucy is changing minds. 
Asked why she takes time 
away from her own family  
to tell her story over 
and over, Lucy explains, 
“Disability from a vaccine-
preventable disease is a 
huge burden on both the 
child and the parents, 
especially in my community. 
When a child is fully 
immunized, the child is 
secure, and the parents  
are too.” 
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mLab
New Horizon for Health Care through  
Mobile Technology
Mobile solutions are reshaping various sectors 
in Kenya, and are taking root in the new age of 
communication. With the rapid advancement in 
mobile technology, the health care industry has 
not been left behind. Mobile technology is helping 
to enhance the delivery of health services and 
communication between public health systems, 
medical services providers, and patients. 
In Kenya, where the doctor to patient ratio is 
1:10,000, the need for innovation in the health 
sector is critical if hospitals and clinics are to offer 
quality services. Additionally, communication 
challenges among health care providers, patients 
and caregivers tends to be extremely frustrating. 
mHealth Kenya has been a local implementing 
partner for the CDC Foundation in the country, 
overseeing and managing mobile technology 
projects in the health sector. Its innovations seek to 
bridge the communication gap between doctors 
and patients and to put health services within the 
public’s reach.
In 2018, CDC—through PEPFAR funding and 
other laboratory stakeholders – collaborated with 
mHealth Kenya, an implementing partner, to 
develop an easy to use mobile application branded 
“mLab.” mLab offers access to real time viral load 
(VL) and early infant diagnosis (EID) results that are 
both secure and confidential. This enables facilities 
that lack proper infrastructure or internet to receive 
results through a secure short message system 
(SMS)-based platform.
The mLab Process 
A summary of how the lab results are transmitted and used by health facilities.
The central reference laboratory (CRL) 
receives samples from facilities  
throughout Kenya for testing.
Once the results are  
released by the CRL,  
facility clinical team members  
and patients using the  
mLab application  
receive results  
through SMS. 
Stakeholders, partners and  
facility users are able to  
access de-identified patient 
data to view dashboards and 
reports for monitoring  
and evaluation.
Through this innovation, health facilities in Kenya 
have experienced reduced turnaround time in 
receiving their patients’  VL and EID results from 
the central reference laboratory. Consequently, 
patient management has been improved because 
of the faster access to results, flagging of actionable 
results and ensuring that decisions for patient 
management are based on actual patient results. 
To date, mLab has been rolled out in over 65% of all 
Kenyan counties, is being used at 731 facilities, and 
has transmitted over 725,000 results to patients.
The mLab initiative has brought together a team of 
experts with a diversity of knowledge, experience, 
and a deep understanding of the health sector. 
The user-friendly format of the mLab app and the 
fact that it does not indicate personal identifying 
information offers a viable and sustainable solution 
for health communication across the country.
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Operation Triple Zero Ignites  
International Interest
Kenya has been recognized globally for its new and 
innovative approach for reaching young people 
living with HIV who account for approximately 
20% (303,700) of all people living with HIV in the 
country. Operation Triple Zero (OTZ) is designed 
to motivate adolescents and young people to take 
responsibility for their own health. The program 
nurtures the potential and strengths of adolescents 
in this regard. These adolescents are engaged as 
‘co-producers’ in their health and motivate their 
peers through positive pressure and forge a shared 
commitment to achieve the three zeroes—zero 
missed clinical appointments, zero missed 
drugs and zero viral load.
Globally, young people (10 to 24 years), especially 
young women, continue to be disproportionately 
affected by HIV. This is the only age group in which 
AIDS-related deaths are not decreasing globally. 
In 2019, 2.1 million people aged between 10 and 
19 years were living with HIV and 260,000 became 
newly infected with the virus.4 
There are many factors that put young people 
at risk of HIV. Adolescence and early adulthood 
are a critical period of development when 
significant physical and emotional changes occur. 
The transition from childhood to adulthood 
is also a time for exploring and navigating 
peer relationships, gender norms, sexuality 
and economic and personal responsibility. 
These factors often lead to suboptimal HIV 
treatment outcomes among this age group due 
to a decrease in follow up, low adherence to 
treatment and low viral suppression.
OTZ PROGRAM COMPONENTS
KEY MOTIVATORS  
for OTZ Participants
  Being a hero!
  Identification with OTZ club
  Regular motivational messages
  Recognition awards
  Ownership of one’s health
  Tailored model of care
OTZ is based on THREE CORE SERVICE PACKAGES targeting AYP:
Adolescent and 
Young Person 
Package
  Comprehensive HIV  
treatment literacy 
  AYP Connectedness 
through OTZ clubs  
and social media
  Leadership and 
empowerment 
  Mentorship and 
motivation 
  Adolescent 
participation 
Healthcare Worker 
Package
  Training on the 
adolescent package 
of care
  Training on the 
pediatric and 
adolescent health 
care 
worker toolkit
  Implementing asset-
based model in AYP 
HIV clinics
Caregiver  
Package
  Caregiver treatment  
literacy training 
  Supporting AYP’s to 
be their own health 
managers
4 UNAIDS Update: Active involvement of young people is key to ending the AIDS epidemic by 2030
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“When I joined secondary school, I experienced a lot of stigma. I stopped taking my 
medications and this led to deterioration in my health…I joined an OTZ club…have taken 
charge of my health.” 
—18 year old adolescent living with HIV
OTZ scale-up in Kenya has realized exponential 
growth from just one facility with 70 adolescents 
enrolled in 2016, to reaching approximately 47,000, 
or just over 60%, of all adolescents living with 
HIV. Data from 19 early-adopter partners show an 
average viral suppression of 85% in Kenyan youth 
enrolled in OTZ. 
Kenya has received global recognition for 
this ground-breaking initiative, which is now 
recommended in the 2019 operational guidelines 
for all PEPFAR countries. In 2018, Kenya hosted 
technical teams from CDC Atlanta as well as staff 
from the U.S. Agency for International Development 
(USAID) and the Department of Defense from 
four countries – Nigeria, Ethiopia, Malawi and 
Mozambique to help them learn how to extend 
the OTZ initiative into their countries’ HIV/AIDS 
programming. 
Adolescents’ ownership of OTZ saves time and 
resources that would otherwise be used for 
counseling, making it easier and cheaper to scale 
up. Under its motto “Heroes for Zeros and Zeros for 
Heroes, It takes a Hero to be a Zero and a Zero to 
be a Hero” young people are demonstrating their 
ability to take the lead over their own health and 
inspire others to do the same. 
In November 2018, CDC Kenya organized a week long site visit with staff from CDC and USAID  
offices located in Nigeria, Ethiopia, Malawi, and Mozambique.
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U.S. Mission Celebrates  
15 Years of PEPFAR in Kenya
The year 2018 was particularly important for 
PEPFAR, as it marked the fifteenth anniversary 
of its enactment. When PEPFAR began, only 
7,800 Kenyans living with HIV were on lifesaving 
antiretroviral treatment. Today, more than 1 million 
men, women and children are on treatment and 
able to live positively. To help celebrate these gains, 
the U.S. Department of State hosted a number of 
initiatives including a World AIDS Day 2018 event 
at one of the first PEPFAR sites, a gender-based 
violence photo exhibition, and a documentary 
highlighting the HIV journey in Kenya. 
World AIDS Day:  
A Day of Celebration and Service
The World AIDS Day 2018 event doubled as 
an opportunity to serve and engage with the 
community in the informal settlement of Kibera, 
one of the largest such settlements in sub-
Saharan Africa. Volunteers from the U.S. Embassy 
painted exterior walls, decorated the pediatric 
ward, and planted flowers and trees – allowing 
for a visual transformation of the health facility’s 
main entrance. The volunteers stepped out into 
the community and saw first-hand the important 
role of health diplomacy and how it contributes 
to improving health and safety globally. In his 
remarks, U.S. Ambassador Robert Godec shared 
that “Today, death and despair have been 
overwhelmingly replaced with hope and life.” 
This was the theme of the WAD 2018 pre-event, 
honoring those lives lost while celebrating the 
lives regained over the last 15 years. The formal 
ceremony also served as the premier of the PEPFAR 
More than 40 U.S. Embassy members volunteered at the 
Kibera Community Health Center —site to over 11,000 
patients that receive free HIV care and treatment.
U.S. Embassy leadership, including Ambassador Robert 
Godec, celebrated  the importance of youth taking 
ownership of their health and getting tested for HIV.
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Kenya documentary, which demonstrated the 
progress made towards controlling HIV and AIDS 
through collaborative efforts. 
Honoring “Champions for Change’
Additionally, the U.S. government launched the 
gender-based violence (GBV) “Champions for 
Change” photo exhibition to honor individuals 
in the community that serve a critical role in 
preventing and responding to acts of GBV. These 
Champions included a Maasai moran (young male 
leader), a police officer, a former street girl, boda 
boda (motorcycle taxi) operators and more. 
Kenya’s Cabinet Secretary (CS) for Education, 
Ambassador Amina Mohamed, Nairobi Women’s 
Representative, Esther Passaris, and Ambassador 
Godec were among the chief guests. In her 
remarks, CS Mohamed highlighted the harrowing 
statistics of school-going children being 
abused on their way to and from school and 
her decision to change official school hours 
nationally. Ambassador Godec remarked, “The 
U.S. government recognizes that ending gender-
based violence is paramount to securing a strong 
and health future for all.” The photo exhibition ran 
during the 16 Days of Activism Against GBV which 
is an international campaign aiming to generate 
awareness and call attention to GBV.
During this period, CDC Kenya and its 
implementing partners reported the following 
accomplishments from fiscal year 2018:
  More than 7.7 million Kenyans know their  
HIV status.
  92% of patients living with HIV and on  
treatment have achieved control of the HIV  
virus (or viral suppression).
  More than 400,000 pregnant women know their 
status. And of those tested HIV positive, 99% are 
on HIV treatment, making it possible for babies 
to be born HIV free.
  Over 190,000 men received a voluntary medical 
male circumcision—97% of CDC Kenya’s annual 
target—to help prevent them from acquiring 
HIV infection.
While the PEPFAR 15 campaign was an important 
reminder of the progress made, we have a small 
window to finish the job. If the global community 
does not control HIV now and use every tool 
available, there is risk of these gains being undone. 
Margaret Waithera, shares her experiences as a  
survivor of abuse who now owns her own business  
and mentors young girls. 
Douglas, a Maasai Moran (young male leader), is recognized for going door to door sensitizing  
his community on the dangers of female genital mutilation.
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Surveillance
CDC Kenya supports the development and implementation of population 
and facility-based disease surveillance systems that are used for data 
collection, analysis, and reporting. These surveillance systems assess 
disease burden in communities, identify outbreaks, guide public health 
action and evaluate the impact of health interventions.
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HIV Survey among Fishing Communities on 
the Islands of Lake Victoria
Fishing communities on the shores of Lake Victoria 
in western Kenya are at high risk of HIV infection. 
Due to their geographic isolation, low literacy 
levels, high mobility, risk behaviors, and the near 
absence of a wide range of basic health services, 
these communities are particularly vulnerable 
to the HIV epidemic. Unfortunately, there have 
been limited population-based surveys among 
these communities that improve understanding 
of HIV epidemiology and inform interventions and 
services for this population.
In 2018, CDC Kenya in collaboration with the 
National AIDS and STI Control Program (NASCOP), 
Kenya Medical Research Institute (KEMRI), and 
University of California, San Francisco (UCSF) 
completed a household survey of fishing 
communities on eight island beaches of Lake 
Victoria. This study aimed to determine the 
prevalence of HIV, risk factors, and HIV service 
coverage among fishing communities. Data on 
demographics, behavior, home-based HIV and 
malaria rapid testing as well as viral load for 
HIV positive persons were collected from the 
participants.
Given the location remote location of the study 
sites, this study presented a number of challenges. 
“We almost capsized on our way to the islands!” 
recalled one of the study investigators. The team 
had to take one to three hour boat rides from 
the mainland across to the islands and back, 
facing harsh conditions such as the hot sun or 
rough waters. Despite the numerous challenges 
experienced, the team persevered and completed 
the study successfully.
Studies such as this one are critical to 
understanding the dynamics of the HIV epidemic 
and moving towards epidemic control. Due to 
untiring efforts of CDC researchers and their 
partners, Kenya’s public health community has an 
increased understanding of how to better serve 
these fishing communities and continue making 
gains towards achieving HIV epidemic control. 
The prevalence of HIV among these fishing communities is 
high, estimated around one-third, making them a priority 
for HIV prevention and treatment.
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Public Health Technical Assistance to Kenya 
Ports of Entry and Border Crossings
In light of recent infectious disease outbreaks 
in Africa, the Government of Kenya recognized 
the need to further improve port health services. 
Effectively mitigating the importation, or 
exportation, of infectious diseases and other public 
health threats requires strong national—and ports 
of entry (POE)—level preparedness and response 
capacity and cross-border collaboration. In 2018, the 
Kenya Ministry of Health’s Port Health Services (PHS) 
adapted and implemented CDC’s Division of Global 
Migration and Quarantine Border Health Capacity 
Discussion Guide. Through this process, tailored 
action plans were developed to address identified 
areas for improvement to strengthen services at 
two ground crossings (Busia and Malaba) and Jomo 
Kenyatta International Airport (JKIA). Busia and 
Malaba POE border Uganda and are the busiest with 
over 3,000 international travelers and 1,600 vehicles 
crossing daily. JKIA is Kenya’s main international 
airport with an average of 109 international and 55 
domestic flights arriving every day and a total of 
20,000 international travelers from Africa and other 
continents using the airport daily. The developed 
action plans included better characterization of 
cross-border population movement, enhancing 
inter-sectoral collaboration at POEs, improving 
community-based surveillance strategies around 
the POE and multisectoral and multi-agency disease 
preparedness and response plans at POEs. The next 
steps include mini-residency for PHS officers to learn 
about quarantine stations operating procedures 
and best practices, develop and finalize a multi-
agency public health emergency response plans 
for the three priority POEs and initiate cross-border 
experience exchange mechanisms through regular 
conference calls. 
Malaba border crossing in western Kenya. Photo from Nation Media Group.
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KENPHIA in the Field
Through PEPFAR, CDC actively participated in the 
implementation of KENPHIA, the Kenya Population-
based HIV Impact Assessment. KENPHIA required 
teams to work extensively across the country, 
including with field-based laboratory work. KENPHIA 
has also provided opportunities to see how PEPFAR 
has improved lives for countless Kenyans. 
In June 2018, Kenya’s Ministry of Health, in 
collaboration with ICAP, an organization within 
Columbia University, launched KENPHIA to 
measure the reach and impact of HIV programs 
in Kenya. KENPHIA included 20,000 randomly 
selected households and interviews from 
approximately 35,000 people across the country. 
Survey participants received household-based 
HIV counseling and testing conducted by trained 
survey staff. KENPHIA will—for the first time—
record population-based HIV estimates for all 47 
counties and provide a national rate for Hepatitis 
B and syphilis prevalence. The results will measure 
national progress toward UNAIDS’ 90-90-90* goals 
and guide policy and funding priorities.
The PEPFAR funding for KENPHIA is coordinated 
and managed through CDC. Staff from the CDC’s 
Division for Global HIV and TB (in headquarters) 
along with staff from CDC Kenya have worked 
together to:
  Advise on the protocol development,
  Facilitate weeks of training sessions for field staff,
  Provide technical assistance with survey 
implementation, and
  Serve as field monitors to ensure adherence to 
survey procedures. 
Dr. Emily Zielinski-Gutierrez, chief of CDC Kenya’s 
Surveillance and Epidemiology Branch, explained 
that “observation of survey procedures occasionally 
allows monitors to hear an individual’s story of 
being diagnosed and receiving life-sustaining 
antiretroviral therapy, affirming the reasons behind 
all the work we do.”
Beyond serving as an expert advisor and key 
contributor to KENPHIA, CDC has demonstrated 
a strong commitment to supporting the 
survey teams that are largely responsible for 
implementing KENPHIA. 
Data collection for KENPHIA wrapped up in 
February 2019. Preliminary survey findings are 
expected to be released in mid-2019 and will likely 
be a major reference for determining future HIV 
programming in Kenya.
*UNAIDS Fast-Track Targets: 90% of people living with HIV diagnosed; 90% of the diagnosed on antiretroviral therapy; and 90% of the treated 
virally suppressed by 2020.
KENPHIA field teams visited remote areas to  
gather data on HIV and other conditions
Anthony Waruru (white shirt), CDC Kenya epidemiologist, 
participates in the study as a field monitor and provides 
technical assistance and feedback to field staff. 
Dr. Kevin De Cock (R), CDC Kenya country director, makes 
it a priority to visit teams in the field and learn about how 
the study is being implemented and accepted.
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When an Outbreak Occurs in an  
Unexpected Location
On June 19, 2018, CDC and KEMRI laboratory staff 
at KEMRI’s Center for Global Health Research in 
Kisumu, Kenya were notified of a suspected case 
of viral hemorrhagic fever in a patient admitted to 
the Siaya County Referral Hospital. The patient, a 
fisherman, had developed a fever four days earlier 
and at the time of sample collection was bleeding 
from the mouth and nose. CDC tested the sample 
for Ebola, Marburg, Crimean-Congo, Yellow fever, 
Rift Valley fever (RVF) and dengue by a laboratory 
technique called polymerase chain reaction (PCR). 
The results identified RVF virus as the cause of the 
fisherman’s illness. Unfortunately, the patient died a 
few hours after the sample was collected.
Rift Valley fever, a mosquito-borne disease that 
primarily affects animals occurs in large outbreaks 
every few years, but these outbreaks have not 
previously affected the counties neighboring Lake 
Victoria. As RVF is not well known by the local 
population, two scenarios emerged during this 
period following the patient’s death. First, the 
deceased family blamed a neighbor for bewitching 
the victim following a recent physical altercation, 
leading to growing hostility in the village. Second, 
when the patient was admitted to the hospital, 
the healthcare workers who handled the case 
were quarantined for observation, but not before a 
number of them had had contact with the patient. 
Even though the patient did not have a history of 
travel outside of Kenya, other infectious disease 
threats such as Marburg which had been recently 
reported in Uganda were a concern. This made the 
confirmatory diagnosis all the more important.
Due to the longstanding relationship with CDC’s 
work in western Kenya, the medical officer reached 
out to CDC and KEMRI to assist with laboratory 
testing. Within six hours, the sample had been 
transported over one hour’s drive away, analysis 
completed, and the results of RVF were shared 
with the hospital. Quarantined staff were released 
under self-observation and the patient’s family was 
informed of the cause of death, thereby reducing 
tension in the village. CDC management in western 
Kenya also mobilized immediate outbreak support 
which included raising awareness across the entire 
county as well as an assessment of the extent 
that animals and people were affected in the 
area. Residents were informed on how to properly 
dispose of dead animals in cases of abortion in 
sheep and cattle – one of the main symptoms 
of the infection. Health officials also instituted 
mosquito vector control by removing, or cleaning, 
mosquito breeding sites such as used tires, plastic 
garbage, water storage or other receptacles that 
accumulate water where mosquitoes can breed. 
The results also enabled the Ministry of Health, the 
Ministry of Agriculture and Livestock, KEMRI and 
CDC to conduct contact tracing.
The timely diagnosis and intervention by CDC 
in western Kenya alleviated additional health 
and economic losses often associated with RVF 
outbreaks and limited further infections. It also 
served as an important reminder that infectious 
disease threats can emerge anywhere at any time, 
and become a threat everywhere.
CDC’s Role in Assessing Risks to Global 
Health Security in Kenya
Assessing the risk of disease emergence and 
spread is a key component of global health 
security. Resources and limited funds for detection, 
prevention and control need to be targeted to 
specific disease threats, either nationally, or to 
at-risk areas in Kenya, where threats are most likely 
to occur and spread. Moreover, risks present in one 
part of the world are informative for Kenya, but it 
cannot be assumed that the risks are the same.
CDC Kenya, along with CDC Atlanta and partners, 
is supporting a wide range of risk assessment 
activities in Kenya, including for Zika, MERS-CoV, 
avian influenza, Rift Valley fever and cholera.
To understand the current risk of Zika infection 
in Kenya, in October 2017, CDC Kenya initiated a 
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cohort study of pregnant women in Mombasa. 
Women enrolled in the study when they first come 
for antenatal care and are followed up monthly 
until delivery. They are then assessed for acute 
Zika infection and the newborns are screened for 
any congenital abnormalities. To date, after testing 
more than 1,000 women, CDC Kenya have not 
identified any cases of Zika infection, suggesting 
that Zika is currently not a major threat to women 
in coastal Kenya.
In Marsabit County, the majority of camels show 
evidence of previous infection with MERS-CoV, yet 
no exposed camel handlers have been identified 
as infected to date. In order to understand the 
risk camels may pose to humans, CDC Kenya and 
partners initiated a longitudinal study in Marsabit 
County among camels and their herders. Young 
camels were enrolled and followed-up with 
bi-weekly testing to assess for acute infection 
with MERS-CoV and to detect the actual virus. 
To date over 200 camels and their handlers have 
been enrolled and testing is ongoing in the 
KEMRI laboratories with additional testing at CDC 
headquarters in Atlanta.
Avian influenza remains a global security threat 
to human and animal health. In 2017, influenza A/
H5N8 was detected among wild and domestic 
birds in on the shores of Lake Victoria in Uganda. 
CDC Kenya responded by conducting a survey of 
more than 3,000 samples of wild bird feces on the 
Kenyan shores of Lake Victoria which identifies low 
pathogen viruses of H5N2. A more comprehensive 
avian influenza surveillance was initiated in the 
main poultry (live bird) markets around Kenya. 
Samples are collected from poultry at the various 
markets and on symptomatic partners during 
monthly visits. 
In 2018, based on previous risk assessments, health 
authorities initiated enhanced surveillance for RVF 
nationally when heavy rain was predicted in Kenya 
which is often linked with outbreaks. To support 
the RVF outbreak response, CDC Kenya, together 
with Global Health Security Agenda partners, 
supported the Government of Kenya in securing 
public diplomacy funds to provide communication 
outreach to 20 high-risk counties as well as 
providing training on sample collection to the 
affected counties. In particular, the CDC supported 
outbreak investigations in Siaya County and disease 
surveillance activities in the Kakuma refugee 
camp detected human RVF infections. This work 
expanded the number of counties now considered 
at risk for future RVF infections.
Lastly, cholera remains a constant epidemic threat 
in Kenya and has been a particular burden since 
2014. Control and prevention fundamentally 
lies with improved WASH (water, sanitation and 
hygiene) practices, however, oral cholera vaccine 
(OCV) can help control outbreaks and provide 
valuable protection while longer-term infrastructure 
is put in place. Yet it is clear that some areas of 
Kenya are more vulnerable than others, leading to 
the concept of cholera “hotspots” where the use 
of OCV and focused WASH efforts would be most 
effective. CDC Kenya and the Division of Foodborne, 
Waterborne and Environmental Diseases are 
supporting WHO, UNICEF and the Ministry of Health 
to complete Kenya’s Cholera Elimination Plan. This 
plan will include a “hotspot” analysis of pre-existing 
data conducted by partners. The data will allow 
policy makers to target WASH and vaccine efforts to 
parts of Kenya considered at highest risk.
CDC Kenya is supporting ongoing infectious disease 
risk assessments though a variety of means including 
outbreak investigations, surveillance, research studies 
and analysis of pre-existing data. These efforts will 
strengthen health security in Kenya by targeting 
resources where they are most needed.
Taking a blood sample from a camel in Marsabit County, 
Kenya to test for zoonotic pathogens including MERS-CoV.
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International Accolades
CDC Kenya not only seeks to improve policies, processes and practices in 
Kenya, but to inform public health progress globally. In 2018, CDC Kenya 
celebrated the praises of multiple staff members that demonstrated impact 
beyond Kenya’s border. This section calls attention to the accolades received 
by CDC Kenya staff members from international colleagues and partners.
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Dr. Elizabeth 
Hunsperger 
Director of Diagnostics and 
Laboratory Systems,
Division of Global Health 
Protection
Dr. Hunsperger was 
recognized by the United Nations Support Office in 
Somalia for her pivotal role in the training of African 
Mission in Somalia (AMISOM) medical officers. Dr. 
Hunsperger led the facilitation of learning sessions 
on dengue fever, malaria and other endemic 
diseases in the Somalia region. In addition, she 
oversaw the activities of a team that provided 
diagnostic assistance to the Somalia mission on 
suspected cases of viral hemorrhagic disease. Her 
efforts were further honored with a Meritorious 
Honor Award from the Department of State for her 
far-reaching support and collaboration.
Dr. Immaculate 
Mutisya
Public Health Specialist,
Division of Global HIV & TB
In Detroit, Michigan, Dr. 
Mutisya received the 2018 
Adolescent Health Initiative 
Excellence Award for her grassroots design and 
implementation of the Operation Triple Zero (OTZ) 
program. Her innovation and responsiveness to the 
needs of adolescents and youth living with HIV was 
highlighted as exceptional work that has impacted 
adolescent health outcomes. OTZ currently has 
more than 47,000 adolescents and youth enrolled 
and is being considered for adoption by 4 other 
countries. 
Dr. Lucy 
Ng’ang’a
Deputy Director for 
Program and Science, 
Division of Global HIV & TB
Dr. Ng’ang’a was the 
recipient of the Lahya Shiimi Award at the annual 
meeting for the U.S. President’s Emergency Plan for 
AIDS Relief (PEPFAR) in Amsterdam, Netherlands. 
She was cited for “her extraordinary ability to 
approach challenges holistically with exceptional 
judgment…managing complex relationships, 
communicating intricate information, respecting 
diverse perspectives, and moving groups toward 
evidence-based decisions and effective partnerships 
that improve the lives of Kenyans.” She also “inspires, 
motivates and offers unwavering and consistent sage 
advice to colleagues as each grows professionally 
along their journey in the fight to end HIV.”
Dr. Marc-Alain 
Widdowson
Director, 
Division of Global Health 
Protectionn
Dr. Gideon 
Emukule
Statistician,  
Influenza Division
Dr. Marc-Alain Widdowson 
and Gideon Emukule  were 
recipients of the Larry J. 
Anderson Award. They were cited “for Outstanding 
Public Health Science and the Charles C. Shepard 
Science Award, in recognition of the work 
published in The Lancet, 2017 on the ‘Estimates of 
global influenza-associated respiratory mortality: a 
modelling study’.
Anthony 
Waruru
Epidemiologist,
Division of Global HIV  
& TB
During the 2018 Centre  
for Global Health (CGH) 
Annual Conference, Mr. Anthony Waruru received 
an award for the best poster presented at the 
Conference on Retrovirals and Opportunistic 
Infections (CROI) of 2017. Anthony’s poster 
looked at finding hidden HIV Clusters to support 
geographic-oriented HIV interventions in Kenya.
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CDC’s Division of Global HIV 
& TB in Atlanta, Georgia offers 
quarterly awards to staff around 
the world for their innovation, 
impact and success. Three of CDC 
Kenya’s teams were recognized 
through this initiatve! 
The CDC Kenya 
Cooperative 
Agreement (CoAg) 
Branch, Finance 
Team, and  
April Kelley 
All three were awarded the team 
award for Advancing Program 
Management and Operations 
with the Budget Marked-up Tool 
(BMT) to assist with increased 
financial accountability for HIV 
and TB funding in-country. The 
CoAg Branch was pivotal in 
tracking financial performance 
and using data for financial 
decision-making. The BMT is 
now being offered as resource 
to other CDC country offices for 
global use.
The CDC Kenya 
Laboratory Branch
CDC Kenya Laboratory Branch 
was awarded the team award for 
Making Significant Contributions 
to Advancing Program and 
Science due to their leadership 
with implementing a remote 
login system to link health 
facilities and testing laboratories. 
This innovation reduces the 
turn-around-time from samples 
collection to the receipt of results 
at facilities thereby improving 
patient management.
Top l-r: April Kelley, Grace Okubo, Rahab Wangui, John Baru, Alice Njoroge,  
Ruth Kuria; Bottom l-r: Emmanuel Okumu, Bernard Warui, Cherubinus, Aroro, 
Carolina Granados, and Jacob Okal
Top l-r: Margaret Mburu, Mercy Njeru, Frank Basiye, Dr. Marie Downer, Frankline 
Mboya, Bottom l-r: Dr. Muthoni Junghae, Raphael Ondondo, Dr. Jane Mwangi, 
Catherine Macharia, Dr. Daniel Kimani, Dr. Ernest Makokha 
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